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Background: This meta-analysis assessed the efficacy of duloxetine versus other oral treatments used after failure
of acetaminophen for management of patients with osteoarthritis.
Methods: A systematic literature review of English language articles was performed in PUBMED, EMBASE, MedLine
In-Process, Cochrane Library, and ClinicalTrials.gov between January 1985 and March 2013. Randomized controlled
trials of duloxetine and all oral non-steroidal anti-inflammatory drugs and opioids were included if treatment
was ≥12 weeks and the Western Ontario and McMaster Universities Index (WOMAC) total score was available.
Studies were assessed for quality using the assessment tool from the National Institute for Health and Clinical
Excellence guidelines for single technology appraisal submissions.
WOMAC baseline and change from baseline total scores were extracted and standardized. A frequentist
meta-analysis, meta-regression, and indirect comparison were performed using the DerSimonian-Laird and
Bucher methods. Bayesian analyses with and without adjustment for study-level covariates were performed using
noninformative priors.
Results: Thirty-two publications reported 34 trials (2 publications each reported 2 trials) that met inclusion criteria.
The analyses found all treatments except oxycodone (frequentist) and hydromorphone (frequentist and Bayesian)
to be more effective than placebo. Indirect comparisons to duloxetine found no significant differences for most of
the compounds. Some analyses showed evidence of a difference with duloxetine for etoricoxib (better), tramadol
and oxycodone (worse), but without consistent results between analyses. Forest plots revealed positive trends in
overall efficacy improvement with baseline scores. Adjusting for baseline, the probability duloxetine is superior to
other treatments ranges between 15% to 100%.
Limitations of this study include the low number of studies included in the analyses, the inclusion of only English
language publications, and possible ecological fallacy associated with patient level characteristics.
Conclusions: This analysis suggests no difference between duloxetine and other post-first line oral treatments
for osteoarthritis (OA) in total WOMAC score after approximately 12 weeks of treatment. Significant results for
3 compounds (1 better and 2 worse) were not consistent across performed analyses.
Keywords: Duloxetine, Osteoarthritis, Meta-analysis, NSAID, Opioid, WOMAC* Correspondence: jam@mdm-inc.com
1Medical Decision Modeling, Inc, 8909 Purdue Road, Suite 550, Indianapolis,
IN, USA
Full list of author information is available at the end of the article
© 2014 Myers et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Myers et al. BMC Musculoskeletal Disorders 2014, 15:76 Page 2 of 16
http://www.biomedcentral.com/1471-2474/15/76Background
Over 50 treatment modalities for osteoarthritis (OA) of
the hip and knee have been evaluated by the Osteoarthritis
Research Society International (OARSI) [1,2]. Oral phar-
macologic modalities included acetaminophen, non-ster-
oidal anti-inflammatory drugs (NSAIDs), and both strong
and weak opioids. Guidelines have recommended acet-
aminophen for first-line use, with NSAIDs and opioids as
second and third lines of treatment [1,3-5]. However, res-
ervations have been expressed concerning the long-term
safety and efficacy of NSAIDs and opioids [1,2,5,6]. Some
reviews have gone further and recommended against their
long-term use [7,8]. Recently published meta-analyses
suggest that currently available oral treatments have only
limited efficacy in the average patient with OA [6]. In
addition, the efficacy seen in trials seems to be impacted
by trial design and baseline factors and may be limited to
the first few weeks of use [6].
Earlier meta-analyses have primarily focused on pain
and have not assessed broader functioning. They have
predominantly investigated single-substance classes, in-
cluded both short- and long-term trials, and sometimes
encompassed both OA and other chronic pain indi-
cations [7-25]. Also, these analyses could not include
evidence for substances that were unavailable when they
were performed, such as duloxetine, a newly available
treatment option in the US.
Duloxetine is a selective serotonin and norepinephrine
reuptake inhibitor (SNRI) that has demonstrated efficacy
in OA in Phase III clinical trials as well as a favorable
adverse event profile across indications [26-28]. Duloxe-
tine is thought to inhibit pain through its enhancement
of serotonergic and noradrenergic activity in the central
nervous system. It is currently indicated in the US for
the management of pain disorders, including diabetic
peripheral neuropathic pain (DPNP), fibromyalgia, and
chronic musculoskeletal pain due to OA and chronic
low back pain [29].
We conducted a systematic literature review followed
by a meta-analysis to assess the efficacy of duloxetine
versus other commonly used post first-line OA treat-
ments, including NSAIDs and opioids. Our study
reflected the chronic nature of OA by including only
trials of 12 or more weeks duration (the recommended
duration for confirmatory trials) [30] and a more inclusive
set of OA symptoms by using the Western Ontario
MacMaster Universities Osteoarthritis Index (WOMAC),
which includes subscales for function and stiffness as
well as pain [31]. We also sought to confirm the
influence of design and baseline factors observed in a
recent OA meta-analysis [6]. Both frequentist and
Bayesian analyses were undertaken to assess the effect
of duloxetine compared to the other available oral
treatments.Methods
Inclusion and exclusion criteria
Randomized controlled trials (RCTs) were included for
OA treatment with duloxetine, NSAIDs or opioids at
dosages consistent with United Kingdom prescribing in-
formation [32]. All included studies were of at least
12 weeks duration and published in English. Articles
were included if they evaluated clinical efficacy using
WOMAC total scores. Studies were excluded that did
not report clinical efficacy of OA, and did not have at
least 2 arms of a treatment of interest, or 1 arm of a
treatment of interest and a placebo arm.
When it was unclear from the title or abstract whether
a study met the criteria, the full paper was acquired and
read. Determination of inclusion/exclusion was per-
formed by 2 persons working independently. When their
conclusions were not in agreement the persons met and
came to a consensus.
Literature search
The literature search was performed on all articles
published between January 1985 and March 2013 in
PUBMED, EMBASE, MEDLINE In-Process & Other
Non-Indexed Citations, Cochrane Central Register of
Controlled Trials, Cochrane Database of Systematic
Reviews, and ClinicalTrials.gov. The search conducted
in PUBMED used the following terms: (ibuprofen OR
naproxen OR diclofenac OR meloxicam OR etoricoxib
OR celecoxib OR mefenamic OR indometacin OR etodo-
lac OR tramadol OR morphine OR codeine OR dihydro-
codeine OR oxycodone OR diamorphine OR methadone
OR hydromorphone OR duloxetine) AND (osteoarthritis)
AND (English [lang]) AND (clinical trial [ptyp]). The
search conducted in the other databases used the same
search terms, but without the specific limitation of clinical
trial publication type.
Data extraction
Data extraction was performed by 1 reviewer and checked
by a second reviewer using a predefined data extraction
form. Discrepancies were resolved by discussion between
reviewers. For each study, reviewers extracted data that
were deemed to potentially impact efficacy outcomes,
such as study population (percent women, mean age,
mean duration of OA), study design (duration, washout
period, flare requirement, concomitant analgesic use, en-
riched enrollment, missing imputation technique), and
outcomes (WOMAC score at baseline, endpoint, and
change from baseline with measures of variance). Studies
were categorized as having a washout period if the publi-
cation mentioned a period of washout or no treatment
before randomization. A study was classified as re-
quiring flare if the publication stated that after the
washout/no treatment period patients were required
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Studies were classified as allowing concomitant analgesic
use if patients could use analgesic medications in addition
to their assigned treatment throughout the study; rescue
medication was not considered concomitant use.
For studies that did not report sufficient data to be
included in the analysis, 3 attempts were made to contact
authors by email to obtain missing information. Studies
were assessed for quality using the assessment tool from
the National Institute for Health and Clinical Excellence
(NICE) guidelines for Single Technology Appraisal sub-
missions [33]. This 7-item questionnaire evaluates each trial
based on randomization, adequate concealment of treat-
ment allocation, similarities between treatment groups,
degree of blinding, balance of withdrawals and dropouts
between treatment groups, reporting of all outcomes mea-
sured, and use of intention to treat analyses. Studies were
assessed by one reviewer and independently checked by aReferences obtained through 
literature search (n = 1045)
PubMed (n = 520)
Embase (n =311)
Medline in-process (n = 52)
Cochrane library (n = 147)


















Articles included in final analysis (n = 32*)
Figure 1 Article selection flow chart. *Reporting 34 studies.second reviewer. Positive responses were tallied for a
total possible score of 7, with higher scores representing
better quality.
Outcome measure
The outcome measure for the meta-analysis was the
change from baseline total WOMAC score as reported
at 12 or more weeks. The WOMAC instrument consists
of 24 questions answered on a 0–4 Likert or 0–100 vis-
ual analogue scale (VAS). The WOMAC has 3 subscales:
function (17 questions), pain (5 questions), and stiffness
(2 questions). A lower WOMAC score indicates fewer
symptoms, thus improvement is shown as a negative
value; negative values of larger magnitude are indicative
of greater efficacy. WOMAC total and subscale scores
are reported inconsistently, with publications reporting
scores on different scales, some subscale scores and not
others, different measures of variance, or no measures ofArticles excluded (n = 921)
 OA (n = 118)
gth of trial (n = 217)
 a treatment of interest (n = 332)
 an outcome of interest (n = 85)
 an RCT (n = 166)
mal study (n = 3)
Articles excluded (n = 72)
 OA (n = 8)
gth of trial (n = 13)
 a treatment of interest (n = 21)
 an outcome of interest (n = 19)
 an RCT (n = 6)
licate study (n = 5)
Articles excluded (n = 20)
 not contain sufficient information for analysis after 
hor contacted up to 3 times (n = 19)
l publication not available (n = 1)
Table 1 Characteristics of all included studies (Alphabetically ordered)

















Abou-Raya et al. 2012 [49]b Duloxetine 144 68.9 50.63 (9.56) −12.40 (14.02) 16 5.7 No Yes Knee
Placebo 144 68.5 50.94 (9.47) −3.96 (15.24) 17 5.6
Afilalo et al. 2010 [50]f Oxycodone 40–100 mg 342 58.2 −27.50 (21.75) 59 No Not mentioned Knee
Study NCT00421928 Placebo 337 58.2 −22.50 (21.00) 59
Baerwald et al. 2010 [51]b Naproxen 1000 mg 156 62.26 −22.54 (20.40) 32.1 Yes No Hip
Placebo 331 63.29 −14.80 (22.27) 37.2
Bensen et al. 1999 [52] Celecoxib 200 mg 202 63 53.13 (17.08) −12.50 (18.06) 72 9 No No Knee
Naproxen 1000 mg 198 62 55.10 (14.58) −12.40 (18.91) 71 10
Placebo 203 62 53.85 (15.42) −6.35 (16.18) 75 11
Bingham et al. 2007a [53] Etoricoxib 30 mg 231 62.1 65.40 (13.03) −24.37 (21.37) 66.2 Yes No Hip/knee
Celecoxib 200 mg 241 62.5 66.20 (13.24) −22.21 (21.66)a 69.7
Placebo 127 62.8 64.67 (13.30) −10.98 (22.14)a 65.4
Bingham et al. 2007b [53] Etoricoxib 30 mg 244 61.9 67.23 (13.24) −24.37 (22.19) 69.7 Yes No Hip/knee
Celecoxib 200 mg 247 62.2 65.59 (14.59) −23.19 (23.29)a 61.9
Placebo 117 60.9 64.98 (13.81) −12.29 (22.63)a 65
Boswell et al. 2008 [54] Celecoxib 200 mg 185 59.7 63.55 (14.70) −23.46 (24.51)a 67 8.8 No No Knee
Placebo 186 60.5 63.37 (13.68) −18.46 (23.46)a 73 8
Burch et al. 2007 [55]f Tramadol 200–300 mg 432 62 34.96 (14.74)g 64 Yes No Knee
Study NCT00833794 Placebo 214 62 35.20 (15.13)g 62
Chappell et al. 2011 [26]b Duloxetine 60–120 mg 128 63.16 51.63 (10.45) −20.50 (11.87) 70 8.14 No Yes Knee
Study NCT00433290 Placebo 128 61.9 53.82 (9.04) −16.25 (12.26) 84 6.74
Chappell et al. 2009 [27]b Duloxetine 60–120 mg 111 62.07 57.10 (12.15) −24.01 (16.07) 63.06 9.04 No Yes Knee
Study NCT00408421 Placebo 120 62.48 56.51 (11.12) −16.81 (13.67) 67.5 9.3
Clegg et al. 2006 [56]b, e Celecoxib 200 mg 318 59.4 47.10 (13.36) −17.95 (14.98) 66.7 10.1 No Yes Knee
Placebo 313 58.2 46.23 (13.49) −14.58 (15.99) 63.9 9.5
DeLemos et al. 2011 [57] Tramadol 200 mg 199 62 61.13 (14.02) −16.24 (24.22) 62.3 8.5 No No Hip/knee
Tramadol 300 mg 199 59.7 60.37 (15.93) −22.10 (24.16) 61.8 7.6
Celecoxib 200 mg 202 60 58.21 (15.26) −25.60 (24.58) 64.9 8




















Table 1 Characteristics of all included studies (Alphabetically ordered) (Continued)
Essex et al. 2012 [58]c Celecoxib 200 mg 296 60 56.15 (15.42) −23.13 (19.71) 64.9 7.2 Yes No Knee
Naproxen 1000 mg 293 60.7 56.56 (15.73) −23.54 (19.61) 67.6 8.5
Fishman et al. 2007 [59] Tramadol 200 mg 107 61 58.42 (13.99) −24.39 (21.19)a 59.8 No Yes Knee
Tramadol 300 mg 105 60 63.74 (15.21) −25.54 (44.61) 65.7
Placebo 224 61 61.29 (14.16) −18.82 (38.32) 61.6
Fleischmann et al. 2006 [60]b Celecoxib 200 mg 444 61.3 50.94 (16.76) −16.67 (18.95) 67.1 6.7 No No Knee
Placebo 231 61.5 48.65 (16.97) −9.69 (16.82) 66.2 6.6
Fleischmann et al. 2001 [61]b Tramadol 200–400 mg 63 62.52 41.60 (20.50)g 65.1 7.94 Yes No Knee
Placebo 66 62.45 50.40 (22.50)g 59.1 7.76
Gana et al. 2006 [36] Tramadol 200 mg 201 59.1 63.77 (13.14) −21.25 (23.92) 63.7 7.7 No No Hip/knee
Tramadol 300 mg 201 58.5 60.10 (14.73) −20.27 (23.81) 59.2 8
Placebo 205 56.4 61.82 (14.82) −14.19 (23.45) 68.8 7.7
Hochberg et al. 2011a [62] Celcoxib 200 mg 242 33.2 −5.56 (40.51)a, h 61.2 Yes Yes Knee
Placebo 124 32.7 66.1
Hochberg et al. 2011b [62] Celecoxib 200 mg 244 33 −4.36 (41.89)a, h 62.7 Knee
Placebo 122 33 63.1
Kivitz et al. 2002 [63] Naproxen 1000 mg 205 60.4 55.91 −18.79 (19.78) 63 9.4 No No Knee
Placebo 205 60.3 55.72 −14.04 (19.71) 64 8.3
Kivitz et al. 2001 [64] Celecoxib 200 mg 207 62 52.29 (16.73) −10.10 (15.92) 65 7.2 Yes No Hip
Naproxen 1000 mg 207 64 51.88 (17.24) −11.98 (16.07) 66 7.3
Placebo 218 64 52.81 (15.60) −4.38 (15.70) 67 7.9
Lehmann et al. 2005 [65]b Celecoxib 200 mg 420 62.9 52.60 (14.93) −15.31 (16.47) 68.3 4.4 Yes yes Knee
Placebo 424 61.7 51.77 (15.09) −11.77 (19.03) 71.9 3.9
Leung et al. 2002 [66] Etoricoxib 60 mg 224 62.93 63.84 (13.89) −22.19 (15.91) 77.2 5.88 Yes No Hip/knee
Naproxen 1000 mg 221 63.16 63.76 (13.36) −21.91 (15.81) 78.3 6.25
Placebo 56 64.09 68.11 (10.83) −13.26 (15.17) 82.1 6.3
Markenson et al. 2005 [67]b, e Oxycodone 10–120 mg 56 62 64.70 (15.71)a −14.93 (26.09) 68 No Yes Hip/knee/spine/other
Placebo 51 64 63.80 (15.00) −0.87 (19.72) 78
Puopolo et al. 2007 [68] Etoricoxib 30 mg 224 62.1 64.95 −24.90 (23.14) 77.7 6.6 Yes Yes Hip/knee
Ibuprofen 2400 mg 213 62.3 63.18 −21.73 (22.49) 73.7 6.7




















Table 1 Characteristics of all included studies (Alphabetically ordered) (Continued)
Rauck et al. 2013 [69] Hydromorphone 16 mg 330 59.5 −17.00 (19.98) 64.2 No Yes Hip/knee
Placebo 331 60 −13.00 (20.01) 63
Schnitzer et al. 2011 [70]b Celecoxib 200 mg 419 61.7 54.90 (14.49) −16.58 (15.24)a 61.3 3.7 No No Hip
Placebo 416 61.4 54.58 (15.11) −10.62 (13.83)a 60.6 3.8
Schnitzer et al. 2011 [71]b Naproxen 1000 mg 254 60 −26.29 (18.71)a 70.5 Yes No Knee
Placebo 257 60.15 −16.04 (18.62)a 72.65
Schnitzer et al. 2010 [72]b Naproxen 1000 mg 227 61.1 70.08 (12.98) −33.33 (20.23)a 67.4 Yes No Knee
Placebo 221 61 69.85 (13.12) −20.42 (20.17)a 71.9
Sheldon et al. 2005 [73]b Celecoxib 200 mg 393 60.2 54.79 (15.45) −16.25 (19.08) 63.1 6.7 No No Knee
Placebo 382 60.8 55.31 (14.36) −9.90 (17.01) 61.3 7
Sowers et al. 2005 [74]c Celecoxib 200 mg 136 61.8 46.20 (22.16) −16.30 (20.99) 62 No No Hip/knee
Naproxen 1000 mg 128 63.6 51.40 (20.36) −14.70 (21.50) 60
Tannenbaum et al. 2004 [75]b Celecoxib 200 mg 481 64.1 50.73 (16.04) −13.96 (16.46) 69.2 5.3 No No Knee
Placebo 243 64.6 51.25 (14.58) −9.79 (16.77) 67.1 4.3
Vojtassak et al. 2011 [76] Hydromorphone 138 65 60.00 (10.11) −17.75 (14.62) 77 No Yes Hip/knee
Placebo 149 66 57.92 (10.36) −17.69 (15.79) 68
Wiesenhutter et al. 2005 [77] Etoricoxib 30 mg 214 63.1 68.68 (16.64) −24.52 (22.97) 70.1 7.9 Yes No Hip/Knee
Ibuprofen 2400 mg 210 61.3 68.13 (17.02) −23.65 (23.13) 70 8.2
Placebo 104 59.5 69.71 (16.52) −14.20 (20.24) 72.1 6.9
Note: avalue imputed by estimating a stiffness subscore from other scores reported for that treatment; bstudy longer than 12 weeks duration; cincluded in Bayesian analysis only, no placebo arm, dwashout is not
considered as complete in studies with concomitant analgesic use; edenotes studies without a washout period; fdenotes studies with enriched enrollment design; gindicates endpoint WOMAC score, change from





























Duloxetine 383 65.00 73.25 7.48
Ibuprofen 423 61.80 71.86 7.44
Naproxen 1889 61.73 68.41 8.26a
Celecoxib 4681 61.63 65.60 6.58a
Etoricoxib 1137 62.41 72.12 6.78a
Tramadol 1507 60.60 62.67 7.95a
Oxycodone 398 58.73 60.27 NR
OROS
hydromorphone
468 59.5b 67.97 NR
Placebo 6560 61.26b 66.97 6.78a
anot all studies reported duration of OA; bone study did not report mean age;
NR = not reported.
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the Likert scores, b) a total of the VAS scores, or c) nor-
malized units with total and subscale scores reported on
0–100 scales [34]. To overcome this issue, WOMAC
total scores were converted to a 0-100 normalized scale
using a direct ratio. If change from baseline was not
reported, it was calculated as the difference between
baseline and endpoint or, if not possible, as the difference
between baseline and a weighted average of multiple
observations during treatment [35]. When subscale scores
were reported without the total score, the total score and
variance were calculated from the subscales. Missing stiff-
ness subscale scores were imputed by substituting the
mean of those reported for that treatment. Studies report-
ing neither the total score nor the pain and function
subscale scores were omitted from the analysis.
Statistical analysis
Frequentist and Bayesian methods were used to assess
the effect of including the direct and indirect data in the
analysis. The frequentist meta-analysis using Bucher
indirect comparisons was chosen because it reports trad-
itional statistical measures, whereas the Bayesian network
meta-analysis allows for inclusion of both direct and indir-
ect information in a single step. In both frequentist and
Bayesian methods, if multiple arms for a treatment were
present in a study at different doses, the arms used were
consistent with the United Kingdom prescribing infor-
mation. For tramadol, the 400-mg daily dose was not
included as it is associated with higher rates of adverse
events and similar efficacy to the 300-mg dose [36].
The frequentist meta-analysis used the difference
between treatment and placebo of the change from base-
line WOMAC score for each active treatment. Random
effects models using the DerSimonion-Laird method
were employed regardless of heterogeneity due to study
design and population dissimilarities [37]. Estimated
treatment effects compared to placebo and compared to
duloxetine were calculated with their 95% confidence
intervals using the Bucher method of indirect compari-
son [38-41]. Frequentist analyses were performed with
Comprehensive Meta-Analysis software (CMA; Biostat,
Englewood NJ) [42]. Publication bias was assessed by
funnel plot with Duval and Tweedie’s trim and fill [37].
Random effects Bayesian network meta-analyses were
performed using the change from baseline score for all
available studies. Bayesian methods described in NICE
Decision Support Unit documents were modified to ac-
commodate continuous data analysis [43,44]. Each trial’s
specific relative treatment effect was assumed to be drawn
from a random effects normal distribution with a com-
mon random effects variance for all treatment compari-
sons. The best model was selected based on the deviance
information criteria (DIC), described in Cooper et al. [45]and Dias et al. [46], and standard deviation (SD), which
provide measures of model fit. The consistency between
direct and indirect evidence was performed using node
splitting methods described by Dias et al. [46]. Estimated
treatment effects compared to placebo and duloxetine
were given with their associated 95% credible inter-
vals as well as the probability of the treatment being
superior to duloxetine. Sensitivity analyses were run
on various scenarios, including adjustment for baseline
scores, flare requirement, and analgesic use. The Bayesian
analyses were conducted using WinBUGS version 1.4.3
(MRC Biostatistics Unit; Cambridge, UK) [47].
Heterogeneity was assessed by calculating the I2 statistic.
Twelve population and study characteristics were assessed
as possible confounding factors by visually inspecting for-
est plots for the magnitude and variability of study
WOMAC scores. These characteristics included washout
period [yes/no], enriched enrollment [yes/no], flare re-
quired [yes/no], chronic pain definition [<6 months/> =
6 months], baseline pain level, concomitant analgesic use
allowed [yes/no], missing imputation technique, quality
assessment, study mean age, study mean duration of OA,
site of OA, and the percent women. When forest plots
suggested a possible relationship, both frequentist and
Bayesian meta-regression were conducted to account for
heterogeneity of treatment effect. Bayesian methods assu-
med the same covariate effect for all active treatments.
Noninformative priors were used for all parameters; a uni-
form distribution was used for random effects variance and
normal distributions with very large variance for all other
parameters, including treatment effect and covariate effect.
Results
Literature search
Figure 1 provides a flow diagram of the article selection
process. Of the initial 1045 articles identified, 124 met
the eligibility criteria for possible inclusion based on
Myers et al. BMC Musculoskeletal Disorders 2014, 15:76 Page 8 of 16
http://www.biomedcentral.com/1471-2474/15/76abstract review. Most excluded studies lacked a treat-
ment of interest or the duration was too short. Thirty-
two articles with 47 active treatment arms reported
sufficient information to be included in the meta-analysis,









Abou-Raya et al. 2012 [49] Yes Yes Yes
Afilalo et al. 2010 [50] Yes Yes Yes
Baerwald et al. 2010 [51] Not clear Not clear Yes
Bensen et al. 1999 [52] Yes Yes Yes
Bingham et al. 2007 [53] Not clear Not clear Yes
Boswell et al. 2008 [54] Not clear Not clear Yes
Burch et al. 2007 [55] Yes Yes Yes
Chappell et al. 2011 [26] Yes Yes Yes
Chappell et al. 2009 [27] Yes Yes Yes
Clegg et al. 2006 [56] Yes Yes Yes
DeLemos et al. 2011 [57] Not clear Yes Yes
Essex et al. 2012 [58] Yes Yes Yes
Fishman et al. 2007 [59] Yes Yes Yes
Fleischmann et al. 2006 [60] Not clear Yes Yes
Fleischmann et al. 2001 [61] Yes Yes Yes
Gana et al. 2006 [36] Yes Yes Yes
Hochberg et al. 2011 [62] Yes Yes Yes
Kivitz et al. 2002 [63] Yes Yes Yes
Kivitz et al. 2001 [64] Yes Yes Yes
Lehmann et al. 2005 [65] Yes Yes Yes
Leung et al. 2002 [66] Yes Yes Yes
Markenson et al. 2005 [67] Yes Yes Yes
Puopolo et al. 2007 [68] Yes Not clear Yes
Rauck et al. 2013 [69] not clear Yes Yes
Schnitzer et al. 2011 [70] Yes Yes Yes
Schnitzer et al. 2011 [71] Not clear Not clear Yes
Schnitzer et al. 2010 [72] Yes Not clear Yes
Sheldon et al. 2005 [73] Yes Yes Yes
Sowers et al. 2005 [74] Yes Not clear Yes
Tannenbaum et al. 2004 [75] Not clear Yes Yes
Vojtassak et al. 2011 [76] Yes Yes Yes
Wiesenhutter et al. 2005 [77] Not clear Yes Yes
a“Was randomisation carried out appropriately?”.
b“Was the concealment of treatment allocation adequate?”.
c“Were the groups similar at the outset of the study in terms of prognostic factors,
d“Were the care providers, participants and outcome assessors blind to treatment a
impact on the risk of bias (for each outcome)?”.
e“Were there any unexpected imbalances in drop-outs between groups? If so, were
f“Is there any evidence to suggest that the authors measured more outcomes than
g“Did the analysis include an intention-to-treat analysis? If so, was this appropriate
hQuality Score is calculated by summing the positive answers to each question (“ye64.9% women). Sixteen articles were found for celecoxib,
9 for naproxen, 5 each for tramadol and etoricoxib, 3 for
duloxetine, and 2 each for ibuprofen, hydromorphone and
oxycodone. Of the 20 other studies identified in the lite-














Yes No No Yes 7
Yes No No Yes 7
Yes No No Yes 5
Yes No No Yes 7
Yes No No Yes 5
Yes No No Yes 5
Yes No No Not clear 6
Yes No No Yes 7
Yes No No Yes 7
Yes No No Yes 7
Yes No No Yes 6
Yes No No Yes 7
Yes Yes, explained No Yes 6
Yes No No Yes 6
Yes No No Yes 7
Yes No No Yes 7
Yes No No Yes 7
Yes No No Yes 7
Yes No No Yes 7
Yes No No Yes 7
Yes No Yes Not clear 5
Yes No No Yes 7
Yes No No Not clear 5
Yes No No Yes 6
Yes No No Yes 7
Yes No No Yes 5
Yes No No Yes 6
Yes No No Yes 7
Yes No No Yes 6
Yes No No Yes 6
Yes No No Yes 7
Yes No No Yes 6
for example, severity of disease?”.
llocation? If any of these people were not blinded, what might be the likely
they explained or adjusted for?”.
they reported?”.
and were appropriate methods used to account for missing data?”.
s” answers to questions 1–4 and 7, and “no” answers to questions 5 &6).
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omission of a measure of variance. One full paper was
unavailable [48].
Table 1 presents the studies included in the meta-
analysis with 5 extracted study characteristics as well as
baseline and change from baseline WOMAC scores. The
duration of nearly all studies was 12 to13 weeks, with a
range of 12 to 26 weeks. The size of treatment arms
ranged from 51 patients in a placebo arm to 481 in a
celecoxib arm. Seven studies did not report baseline
WOMAC scores. Three studies were identified in which
complete WOMAC scores were not reported in the pub-
lication, but were available on clinicaltrials.gov. These
studies are identified in the table with both the publica-
tion reference and the NTC number from clinicaltrials.
gov. Table 2 presents descriptive statistics of the inclu-
ded studies grouped by treatment. In Table 3 the quality
assessments of the included studies are presented. Of the
32 included articles, 26 (81%) had a quality score of 6 or 7
(maximum score 7) and the other 6 studies had a quality
score of 5, indicating that the included studies were of
sufficiently high quality. A funnel plot assessing publica-
tion bias, run on all studies as not enough studies per
compound were available, was roughly symmetrical, with
slightly more studies on the left, indicating little effect of
publication bias on the results of this analysis (Figure 2).
Missing publications have been imputed using Duval and
Tweedie’s trim and fill and appear as solid points among
the actual publications depicted as circles [37]. This method
suggests that possible missing studies would trend to non-
significant differences in means.
Statistical results
Results of both the frequentist and Bayesian analyses are
shown in Table 4. The frequentist approach analyzed 32 ofFigure 2 Funnel plot of standard error by difference in mean. Note: othe 34 studies, excluding Sowers et al. [74] and Essex et al.
[58] due to the lack of placebo arms. All active treatments,
except hydromorphone and oxycodone, were found to
statistically improve the WOMAC total score compared
to placebo. Indirect comparisons to duloxetine using the
Bucher method found all confidence intervals but eto-
ricoxib encompassed zero, indicating the differences
between duloxetine and all treatments except etoricoxib
were not statistically significant. Two compounds, ibu-
profen and etoricoxib, had an I2 of zero while naproxen,
celecoxib, duloxetine, oxycodone, hydromorphone, and
tramadol had I2s of 52%, 33%, 44%,72%, 64%, and 58%,
respectively, indicating substantial heterogeneity [78,79].
However, the direction of the treatment effect was the
same for all but one study; the magnitude of the treatment
effect in these studies was the source of heterogeneity.
The Bayesian network meta-analysis included all 34
studies. Figure 3 depicts the network of direct and indir-
ect evidence. As shown in Table 4, the results lead to
similar conclusions as the frequentist results, as all 95%
credible intervals of the difference between duloxetine
and active treatments included zero.
To explain heterogeneity/inconsistency, we graphically
explored the association of relative effect of the active
treatment versus placebo with study-level covariates.
Forest plots were generated for each population and
study characteristic showing the difference between pla-
cebo and treatment of the change from baseline, ordered
by the value of the characteristic (see Additional files 1,
2, 3, 4, 5, 6, 7, 8, 9, 10, 11). Figure 4 is the forest plot for
baseline WOMAC scores. A visual association was indi-
cated between baseline and change from baseline scores,
with a higher baseline score associated with a larger
negative (improved) change from baseline. Figure 5 is a
verifying scatter plot showing the trial-level baseline= actual publication; ● = hypothetical omitted study.
Table 4 Indirect comparison: results for WOMAC total score change from baseline
Duloxetine Ibuprofen Naproxen Celecoxib Etoricoxib Tramadol Oxycodone Hydromorphone
Frequentist analysis
Number of studies 3 2 7f 14f 5 5 2 2
Change from baseline vs. placebo, mean −6.48 −8.34 −8.27 −5.78 −11.04 −3.99 −8.56 −2.13
95% CI [−9.09, −3.88] [−11.98, −4.71] [−10.27, −6.28] [−6.86, −4.69] [−13.24, −8.84] [−6.74, −1.23] [−17.23, 0.11] [−5.99, 1.72]
I2 (%) 44.35 0 51.92 32.49 0 58.03 71.99 63.54
Indirect vs. Duloxetine a NA −1.86 −1.93 0.71 −4.56 2.36 −2.07 4.35
95% CIb NA [−6.33, 2.62] [−4.70, 0.84] [−2.12, 3.53] [−7.97, −1.15] [−1.00, 5.73] [−11.13, 6.98] [−0.31, 9.01]
Bayesian analysis
Number of studies contributing to each compoundc 3 2 9 16 5 5 2 2
Change from baseline vs. placebo, meand −6.47 −7.85 −7.9 −6.2 −9.53 −2.89 −7.04 −2.19
95% CI [−9.27, −3.7] [−11.59, −4.18] [−9.54, −6.27] [−7.46, −5.03] [−11.86, −7.3] [−5.41, −0.54] [−11.35, −2.95] [−5.52, 1.21]
Indirect vs. Duloxetinea NA −1.38 −1.43 0.27 −3.07 3.57 −0.58 4.28
95% CIb NA [−6.04, 3.21] [−4.65, 1.81] [−2.78, 3.28] [−6.66, 0.49] [−0.17, 7.19] [−5.69, 4.32] [−0.01, 8.69]
Probability Duloxetine is Superior NA 0.28 0.19 0.57 0.04 0.97 0.41 0.97
Number of studies contributing to each compound
for adjusted for baseline WOMAC scoree
3 2 7 14 5 3 1 1
Indirect vs. Duloxetine adjusted for baseline WOMAC scoree NA 1.85 0.24 0.83 −0.43 4.92 −4.67 8.19
95% CIb NA [−2.13, 5.9] [−2.36, 2.87] [−1.45, 3.14] [−3.4, 2.57] [1.51, 8.34] [−13.24, 4.07] [3.84, 12.56]
Probability Duloxetine is Superior NA 0.82 0.57 0.76 0.38 1 0.15 1
aA positive (negative) result indicates that the compared treatment is worse (better) than duloxetine.
bIf zero does not fall between the upper and lower bounds the null hypothesis (treatments are the same) is rejected.
cThere are fewer studies in the adjusted analyses.
dRandom effects model.
eRandom effects model adjusting for baseline excluding trials with no baseline.




















Figure 3 Network of evidence including direct and indirect comparisons. Note: the numbers represent number of comparisons between
treatments.
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http://www.biomedcentral.com/1471-2474/15/76WOMAC scores between 45 and 70 and the relative treat-
ment effect appearing to increase as the trial-level baseline
increases. A frequentist meta-regression confirmed an as-
sociation between the baseline and change from baseline
scores (p < 0.0001) with an R2 of 0. 573, indicating much
of the observed improvement in symptoms was associated
with a higher baseline level of symptoms.
Bayesian meta-regression models including study-level
covariates were used to evaluate the extent to which
covariates accounted for heterogeneity of treatment effects.
Three models including study-level covariates yielded
lower, similar DICs. (See Table 5). The model including the
baseline score yielded both the lowest DIC and a subs-
tantially smaller SD of heterogeneity. Therefore, the model
including the baseline score was preferred. Adjusted for
baseline score, credible intervals of all treatments but
tramadol and hydromorphone included zero, indicating
no evidence of difference from duloxetine. In the cases of
tramadol and hydromorphone, duloxetine demonstrated
evidence of a clear advantage. When adjusted for baseline,
the probability of duloxetine being superior increased for
naproxen (19% to 57%), ibuprofen (28% to 82%), and
etoricoxib (4% to 38%), but went down for oxycodone
(41% to 15%).Discussion
Our analysis employed the WOMAC, a common instru-
ment in OA trials, with subscales for function, pain, and
stiffness. It is, therefore, a broader measure of OA health
than instruments that focus solely on pain. Randomized
controlled trials and meta-analyses in OA commonly focus
on the difference between the treatment and placebo arms
of improvement from baseline to endpoint. Although a
commonly reported measure in meta-analysis is the stan-
dardized mean difference Cohens d, we chose to report the
unstandardized total WOMAC score, as it is a more mean-
ingful outcome to clinicians. In the absence of consistent
statistical significance, clinical relevance was not discussed.
Because OA is a chronic condition, studies were included
only with a treatment duration of at least 12 weeks, the
current recommended minimum duration of confirmatory
chronic pain trials [30]. This has not been universal practice
in other meta-analyses of OA [8-11,15-17].
With our choice of the WOMAC composite score as
the outcome of interest, we chose a continuous endpoint
(mean and standard deviation) rather than a dichotomous
variable. It is recognized that others recommend the use
of dichotomous variables (eg, 50% reduction in pain score)
for evaluation of chronic pain trials. This recommendation
Study name Subgroup within study Baseline WOMAC Statistics for each study Difference in means and 95% CI
Difference Lower Upper 
in means limit limit
Clegg 2006 Celecoxib 46.670 -3.37 -5.79 -0.95
Fleischmann 2006 Celecoxib 50.153 -6.98 -9.88 -4.08
Abou-Raya 2012 Duloxetine 50.781 -8.44 -11.82 -5.06
Tannenbaum 2004 Celecoxib 50.904 -4.17 -6.73 -1.61
Lehmann 2005 Celecoxib 52.186 -3.54 -5.94 -1.14
Kivitz 2001 Naproxen 52.355 -4.75 -8.57 -0.93
Kivitz 2001 Celecoxib 52.558 -5.72 -8.73 -2.71
Chappell 2011 Duloxetine 52.724 -4.25 -7.21 -1.29
Bensen 1999 Celecoxib 53.490 -6.15 -9.49 -2.81
Bensen 1999 Naproxen 54.471 -6.05 -9.49 -2.61
Schnitzer 2011 (CR) Celecoxib 54.740 -5.96 -7.93 -3.99
Sheldon 2005 Celecoxib 55.048 -6.35 -8.90 -3.80
Kivitz 2002 Naproxen 55.813 -7.60 -10.62 -4.58
Chappell 2009 Duloxetine 56.796 -7.20 -11.04 -3.36
Vojtassak 2011 Hydromorphone 58.918 -0.06 -3.59 3.47
DeLemos 2011 Celecoxib 59.079 -7.87 -12.65 -3.09
Fishman 2007 Tramadol 200 60.430 -5.57 -13.35 2.21
DeLemos 2011 Tramadol 200 60.619 1.49 -3.27 6.25
Gana 2006 Tramadol 300 60.827 -6.08 -10.68 -1.48
Fishman 2007 Tramadol 300 62.072 -6.72 -16.09 2.65
Gana 2006 Tramadol 200 62.785 -7.06 -11.67 -2.45
Boswell 2008 Celecoxib 63.458 -5.00 -9.88 -0.12
Puopolo 2007 Ibuprofen 63.653 -7.30 -12.36 -2.24
Markenson 2005 Oxycodone 64.271 -14.06 -22.89 -5.23
Leung 2002 Naproxen 64.644 -8.65 -13.25 -4.05
Leung 2002 Etoricoxib 64.694 -8.93 -13.55 -4.31
Puopolo 2007 Etoricoxib 64.821 -10.47 -15.59 -5.35
Bingham 2007a Etoricoxib 65.139 -13.39 -18.10 -8.68
Bingham 2007b Celecoxib 65.400 -10.90 -16.06 -5.74
Bingham 2007a Celecoxib 65.666 -11.23 -15.95 -6.51
Bingham 2007b Etoricoxib 66.519 -12.08 -17.08 -7.08
Wiesenhutter 2005 Ibuprofen 68.653 -9.45 -14.67 -4.23
Wiesenhutter 2005 Etoricoxib 69.017 -10.32 -15.50 -5.14
Schnitzer 2010 Naproxen 69.969 -12.91 -16.65 -9.17
Hochberg 2011a Celecoxib Missing -5.56 -14.25 3.13
Hochberg 2011b Celecoxib Missing -4.36 -13.42 4.70
Rauck 2013 Hydromorphone Missing -4.00 -7.05 -0.95
Baerwald 2010 Naproxen Missing -7.74 -11.87 -3.61
Schnitzer 2011 (SAR) Naproxen Missing -10.25 -13.49 -7.01
Afilalo 2010 Oxycodone Missing -5.00 -8.22 -1.78
Burch 2007 Tramadol Missing -0.24 -2.68 2.20
Fleischmann 2001 Tramadol Missing -8.80 -16.24 -1.36
DeLemos 2011 Tramadol 300 Missing -4.37 -9.12 0.38
-20.00 -10.00 0.00 10.00 20.00
Favors Treatment Favors Placebo
Figure 4 Forest plot by baseline WOMAC showing difference in change from baseline. Note: the lower limit in the Markenson study
extends beyond the −20.00 scale of the plot.
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http://www.biomedcentral.com/1471-2474/15/76is based on the benefits of treatment being frequently un-
equally distributed, typically presenting as a u-shaped dis-
tribution [81]. The WOMAC, however, is rarely reported
in this manner, and our aim was to report the broader def-
inition of health that the WOMAC encompasses, rather
than pain alone.
Song et al. [41] suggests that judicious use of meta-
analytical methodology can come to similar results as direct
head-to-head evidence. It is frequently not possible, how-
ever, to fully account for differences in patient populations,
the impact of different trial designs, and additional hidden
confounders. For example, some of the trials applied flexible
dose regimens (including 1 duloxetine trial) while others
applied fixed dose regimens; this could impact comparative
results. Enriched enrollment, a treatment run-in after
screening to titrate patients up to optimal tolerability, is fre-
quently used in opioid trials due to their well-known dosing
requirements. NSAID trials, on the other hand, tend toexclude patients with a known bleeding risk or cardio-
vascular risk factors due to NSAIDs’ known safety profile.
In the case of duloxetine, and in contrast to most other
trials, a washout of previous NSAIDs was not enforced.
Patients in duloxetine trials were allowed to continue
(but not increase) treatment with NSAIDs with a higher
proportion of patients receiving NSAIDs in placebo arms.
Because this design feature only applied to duloxetine trials,
they could not be accounted for overall. Such aspects can
limit the interpretation and generalizability of meta-analytic
results.
Statistical analyses were performed using both fre-
quentist and Bayesian methods. Frequentist methods
have the advantage of using more familiar concepts and
terminology. Bayesian network meta-analysis methods
have the advantage of using all the data available, such
as arms from active treatment controlled trials. In this
study both methods produced similar results.
Figure 5 Correlation between baseline WOMAC score and the relative effect of active treatments and placebo.
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http://www.biomedcentral.com/1471-2474/15/76Our results mirror similar findings from previous studies.
A 1997 study could not recommend a choice of NSAID
therapy [21]. A more recent meta-analysis commissioned
by NICE did not find a statistically significant difference
among NSAIDs [82]; guidelines treat NSAIDs as a class
differentiated primarily by adverse events [2,3]. A meta-
analysis of the short-term efficacy of treatments for OA of
the knee found no statistical difference in pain relief
between NSAIDs and opioids [6]. For duloxetine, our ana-
lysis repeats findings from previous studies in other pain
indications. For both DPNP and fibromyalgia, duloxetine
has been shown to be of similar efficacy to alternative
treatment options [83,84]. Our study found a significantTable 5 Comparison of Bayesian modelsa
Random effects
Model DIC Heterogeneity SD
Without adjustment 128.29 1.62
Without adjustment excluding





Analgesic use 105.88 1.09
aA lower DIC indicates a better fit of the model. A difference of 3 in the DIC
between 2 models is usually meaningful [80].relationship between baseline symptoms and the magni-
tude of treatment effect. The related issue of the influence
of flare design in trials of NSAIDs has previously been
noted [7,85].
A limitation of this meta-analysis was the low number
of studies available for analysis. Four or more studies
were available for celecoxib, naproxen, tramadol, and
etoricoxib. For all other treatments, 3 or fewer studies
were found. Eight studies were omitted from the Bayes-
ian adjusted for baseline WOMAC analysis, due to the
omission of baseline scores in study publications. These
numbers were, however, similar to several other meta-
analyses in OA [7,8,18,21]. Limiting the literature search
to English language publications may have lead to missed
RCTs. However, a study examining the effect of an
English-language restriction in systematic reviews and
meta-analyses found no evidence of bias as a result of the
restriction [86]. The funnel plot suggests that publication
bias, if any, was towards the exclusion of statistically non-
significant studies, further supporting our findings of no
difference among comparators. Another limitation of this
study is the potential for ecological fallacy associated with
patient level characteristics. For example, the mean base-
line WOMAC score used in the regression analysis could
represent a wide variety of patient level baseline scores. A
study by Lange et al. [13] points out that imputed data
may bias results, showing benefit of treatment where no
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http://www.biomedcentral.com/1471-2474/15/76benefit is seen in the non-imputed data. Thus, the imput-
ation methods used in several of the included studies could
have introduced bias in the results However, its reported
effect size seems to be in the range of alternative opioid
treatment options such as tramadol or oxycodone [50,87].
Conclusions
This meta-analysis found no difference between duloxe-
tine and other post-first line oral treatments for OA in the
total WOMAC score after approximately 12 weeks of
treatment in a consistent manner. Etoricoxib was more
effective than duloxetine in the frequentist analysis and re-
sulted in a 96% probability of being better than duloxetine
in the nonadjusted Bayesian analysis. After adjustment for
baseline pain score, however, duloxetine showed evidence
of superiority to both tramadol and hydromorphone, but
not for the other treatments, including etoricoxib.
Additional files
Additional file 1: Forest plot by washout showing difference in
change from baseline. Note: the lower limit in the Markenson study
extends beyond the −20.00 Scale of the plot.
Additional file 2: Forest plot by concomitant analgesics showing
difference in change from baseline. Note: the lower limit in the
Markenson study extends beyond the −20.00 Scale of the plot.
Additional file 3: Forest plot by flare requirement showing
difference in change from baseline. Note: the lower limit in the
Markenson study extends beyond the −20.00 Scale of the plot.
Additional file 4: Forest plot by mean age showing difference in
change from baseline. Note: the lower limit in the Markenson study
extends beyond the −20.00 Scale of the plot.
Additional file 5: Forest plot by duration of OA showing difference
in change from baseline. Note: the lower limit in the Markenson study
extends beyond the −20.00 Scale of the plot.
Additional file 6: Forest plot by site of OA showing difference in
change from baseline. Note: the lower limit in the Markenson study
extends beyond the −20.00 Scale of the plot.
Additional file 7: Forest plot by percentage women showing
difference in change from baseline. Note: the lower limit in the
Markenson study extends beyond the −20.00 Scale of the plot.
Additional file 8: Forest plot by enriched enrollment showing
difference in change from baseline. Note: the lower limit in the
Markenson study extends beyond the −20.00 Scale of the plot.
Additional file 9: Forest plot by chonic pain definition showing
difference in change from baseline. Note: the lower limit in the
Markenson study extends beyond the −20.00 Scale of the plot.
Additional file 10: Forest plot by missing imputation technique
showing difference in change from baseline. Note: the lower limit in
the Markenson study extends beyond the −20.00 Scale of the plot.
Additional file 11: Forest plot by quality assessment score showing
difference in change from baseline. Note: the lower limit in the
Markenson study extends beyond the −20.00 Scale of the plot.
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